Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Plos One|August 19, 2016
Experiences and Perspectives of Polycystic Kidney Disease Patients following a Diet of Reduced Osmoles, Protein, and Acid Precursors Supplemented with Water: A Qualitative StudyJacob M Taylor, Lauren Ptomey, Jill M Hamilton-Reeves, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 26, 2016
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 TrialVicente E Torres, Eiji Higashihara, Olivier Devuyst, et al.
Kidney International|January 20, 2012
Evaluation of urine biomarkers of kidney injury in polycystic kidney diseaseChirag R Parikh, Neera K Dahl, Arlene B Chapman, et al.
The New England Journal of Medicine|November 6, 2012
Tolvaptan in patients with autosomal dominant polycystic kidney diseaseVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 10, 2011
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experienceEiji Higashihara, Vicente E Torres, Arlene B Chapman, et al.
The Journal of Clinical Investigation|May 12, 2015
Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney diseaseLi Chen, Xia Zhou, Lucy X Fan, et al.
Journal of the American Society of Nephrology : JASN|November 17, 2006
Early embryonic renal tubules of wild-type and polycystic kidney disease kidneys respond to cAMP stimulation with cystic fibrosis transmembrane conductance regulator/Na(+),K(+),2Cl(-) Co-transporter-dependent cystic dilationBrenda S Magenheimer, Patricia L St John, Kathryn S Isom, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 3, 2009
MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancementKyongtae T Bae, Cheng Tao, Fang Zhu, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 19, 2015
Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 TrialRon T Gansevoort, Esther Meijer, Arlene B Chapman, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 15, 2017
Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney DiseaseMichel Chonchol, Berenice Gitomer, Tamara Isakova, et al.
Pageof 8